Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (GB:0R1F)
LSE:0R1F
Holding GB:0R1F?
Track your performance easily
0R1F Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$39.35 - $57.62
Previous Close$52.14
Volume4.82K
Average Volume (3M)32.85K
Market Cap
$105.83B
Enterprise Value$151.62B
Total Cash (Recent Filing)$6.65B
Total Debt (Recent Filing)$52.39B
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Oct 31, 2024EPS Estimate
$1.55Last Dividend Ex-Date
Oct 04, 2024Dividend Yield4.54%
Share Statistics
EPS (TTM)-3.26
Shares Outstanding2,027,395,178
10 Day Avg. Volume14,944
30 Day Avg. Volume32,849
Standard Deviation0.07
R-Squared0.08
Alpha0.00393
Financial Highlights & Ratios
Price to Book (P/B)6.22
Price to Sales (P/S)2.28
Price to Cash Flow (P/CF)11.40
P/FCF Ratio12.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.26
Enterprise Value/Gross Profit4.42
Enterprise Value/Ebitda44.06
Forecast
1Y Price Target
$50.32Price Target Upside-3.49% Downside
Rating ConsensusHold
Number of Analyst Covering16
Bristol-Myers Squibb News
Bulls Say, Bears Say
Bulls Say
Market StrategyCobenfy will have ~18 months of first-entry advantage.
Regulatory ApprovalFDA approved BMY's Cobenfy for the treatment of schizophrenia, validating the acquisition of Karuna and giving Bristol another key top-line driver.
Safety ProfileAbsence of a black box warning on the label is a clear positive, underscoring the drug's differentiated safety/tolerability profile.
Bears Say
Competitive RiskRisk is seen from a steady flow of competitor data/updates coupled with the broader risk of unwind after the recent macro rotation.
EarningsNearly 75% of Bristol's 2Q top-line beat was driven by the Legacy Portfolio and inventory-driven outperformance, suggesting a lower quality beat.
Patent ExpirationsNo sales growth during 2023-30 given heavy patent expiration pressures.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.07% Insiders
21.35% Mutual Funds
0.49% Other Institutional Investors
54.71% Public Companies and
Individual Investors
0R1F FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest share price was $39.35 and its highest was $57.62 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Currently, no data Available
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Oct 31, 2024 which is in 17 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Jul 26, 2024. The company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.45.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Overvalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 4.54%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is $1.55.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,027,395,100 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $2.07 in its last earnings report, beating expectations of $1.62. Following the earnings report the stock price went up 11%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Among the largest hedge funds holding Bristol-Myers Squibb’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb’s shares valued at 976M.
---
Bristol-Myers Squibb Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$50.32 (-3.49% Downside)
$50.32 (-3.49% Downside)
Blogger Sentiment
Bullish
GB:0R1F Sentiment 98%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.19%
12-Months-Change
Fundamentals
Return on Equity
-26.70%
Trailing 12-Months
Asset Growth
1.24%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
0R1F Company Deck
---
0R1F Earnings Call
Q2 2024
0:00 / 0:00
---
0R1F Revenue Breakdown
27.12% Eliquis
20.02% Opdivo
13.55% Revlimid
8.00% Orencia
31.31% Other
---
0R1F Stock 12 Month Forecast
Average Price Target
$50.32
▼(-3.49% Downside)
Technical Analysis
Best Analysts Covering 0R1F
1 Year
1 Year Success Rate
13/19 ratings generated profit
1 Year Average Return
+8.25%
reiterated a sell rating 4 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +8.25% per trade.
---